Manhattan Scientifics Announces Commercial Introduction Of NanoMRX Precision Nanoparticles

In Collaboration with Azano Biotech, NanoMRX Precision Nanoparticles Now Available for Cell Separation, Targeted Therapy, MRI Contrast, Magnetic Particle Imaging

ALBUQUERQUE, N.M.--()--Manhattan Scientifics (OTCQB: MHTX) announced today a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase.

The nanoparticles are manufactured by Senior Scientific, a division of Manhattan Scientifics, primarily to support Senior Scientific’s NanoMRX cancer detection technology. NanoMRX nanoparticles are uniquely precise and reproducible for consistent results. This is the first time they will be made available for use outside of Senior Scientific’s own programs.

The NanoMRX nanoparticles are manufactured to a precision not available with other iron oxide nanoparticles on the market. For discriminating researchers and precise applications, the NanoMRX nanoparticles will remove experimental variability normally associated with nanoparticles and improve results.

Typically, only a small portion of nanoparticle lots from existing suppliers are actually the size requested. NanoMRX particles are provided in sizes from 5nm to 30nm, with a variation of only +/- 0.5nm.

Senior Scientifics’ president, Gerald Grafe stated, “We developed these high precision nanoparticles for our own cancer detection technology. Now we are pleased to make them available for other applications. We believe Azano is a great partner for this effort, because they already reach the community who will benefit most from the use of our precision NanoMRX nanoparticles.

“The market for precision nanoparticles is still in its infancy but early indications suggest a good deal of interest from a number of potential users,” Grafe continued.

Michael Perrine, CEO of Azano Biotech, said, “Nanoparticles are increasingly important in biomedical technologies. We are eager to make Senior Scientifics’ high precision nanoparticles available to the industry. We anticipate applications in separation, targeting, MRI contrast and Magnetic Particle Imaging (MPI).”

Senior Scientific, a unit of Manhattan Scientifics Inc., is pioneering the NanoMRX technology, driving it from “bench to bedside.” The technology uses non-toxic NanoMRX iron oxide nanoparticles and ultrasensitive magnetic detection for a highly sensitive and very specific approach to cancer detection that can locate and measure tumors one millionth the size detectable by X-Rays and MRI.

Azano Biotech is committed to providing essential research tools to the scientific community that will accelerate biomedical discovery and ultimately improve human health.

About Manhattan Scientifics

Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal, is focused on the commercialization of disruptive technologies in the nano-medicine space. It has achieved several critical milestones in the development of its proprietary technology for the very early detection of cancer. The company is also at work with its licensed NYSE "partner" to commercialize medical prosthetics applications for its patented ultra-fine-grain nanotechnology metals.

About Azano Biotech

Azano Biotech is a privately held company located in Albuquerque, NM. Azano is focused on providing the essential research tools to the scientific community that will accelerate biomedical discovery and ultimately improve human health. Azano is committed to providing quality tools that the international research community expects and demands; thus, we encourage and welcome input from our valued customers.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contacts

Manhattan Scientific
Marvin Maslow, 917-923-3300
Email: marvin@mhtx.com
or
Corporate Advisory/PR
Fastnet Advisors
Anthony Furey, 631-665-1234
mtfurey@fastnetadvisors.com
or
Hawk Associates
Frank Hawkins, 305-451-1888
f.hawkins@hawkassociates.com
or
European Contact:
Herbert Strauss, +43-316-296-316
herbert "at" eu-ir.com

Release Summary

Manhattan Scientifics Announces Commercial Introduction Of NanoMRX High Precision Nanoparticles that were initially developed for cancer detection technology.

Sharing

Contacts

Manhattan Scientific
Marvin Maslow, 917-923-3300
Email: marvin@mhtx.com
or
Corporate Advisory/PR
Fastnet Advisors
Anthony Furey, 631-665-1234
mtfurey@fastnetadvisors.com
or
Hawk Associates
Frank Hawkins, 305-451-1888
f.hawkins@hawkassociates.com
or
European Contact:
Herbert Strauss, +43-316-296-316
herbert "at" eu-ir.com